drugset
drugset / Trial / NCT04198558

A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

NCT04198558 ↗

Phase 1 Completed 64 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.

Timeline

Start
2019-11-29
Primary completion
2022-02-23
Completion
2022-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI0618 Monoclonal antibody — Intravenous

Indications

chronic pain syndrome